Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Draft Guidance for Industry on Providing Regulatory Submissions in Electronic Format-Drug Establishment Registration and Drug Listing, 816-819 [E9-108]
Download as PDF
<![CDATA[
816
Federal Register / Vol. 74, No. 5 / Thursday, January 8, 2009 / Notices
style than they were prior to
participating in the training? Cross-site
evaluation data will be collected on an
annual basis throughout the five-year
funding period. Pre-test and follow-up
versions of the survey are expected to
require approximately 10 to 15 minutes
to complete. Estimated response time
for the follow-up survey includes time
for respondents to access the Web-based
survey, complete the survey online, and
electronically submit the survey.
Respondents will not need to
implement a recordkeeping system or
compile source data in order to
complete the survey. Where possible,
fields in the follow-up version of the
survey will be pre-filled with static data
from the respondents pre-test (e.g.,
demographics, agency type) in order to
further expedite completion of the
survey and minimize respondent
burden.
Respondents: Infant Adoption
Awareness Program Trainees.
ANNUAL BURDEN ESTIMATES
IAATP: Trainee Survey Pre-Test Administration .............................
IAATP: Trainee Survey Follow-Up Administration ...........................
Estimated Total Annual Burden
Hours: 300.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Administration, Office of Information
Services, 370 L’Enfant Promenade, SW.,
Washington, DC 20447, Attn: ACF
Reports Clearance Officer. All requests
should be identified by the title of the
information collection. E-mail address:
infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Fax: 202–395–6974,
Attn: Desk Officer for the
Administration for Children and
Families.
Dated: October 1, 2008.
Janean Chambers,
Reports Clearance Officer.
Editorial Note: This document was
received at the Office of the Federal Register
on January 5, 2009.
[FR Doc. E9–100 Filed 1–7–09; 8:45 am]
erowe on PROD1PC63 with NOTICES
BILLING CODE 4184–01–P
Number of
responses per
respondent
Number of
respondents
Instrument
1,200
1,200
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2005–N–0464] (formerly
Docket No. 2005N–0403)
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Draft Guidance for
Industry on Providing Regulatory
Submissions in Electronic Format—
Drug Establishment Registration and
Drug Listing
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by February 9,
2009.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0045. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3794.
VerDate Nov<24>2008
13:57 Jan 07, 2009
Jkt 217001
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
Average burden
hours per
response
1
1
Total burden
hours
0.15
0.10
180
120
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Draft Guidance for Industry on
Providing Regulatory Submissions in
Electronic Format—Drug Establishment
Registration and Drug Listing;
Availability; Registration of Producers
of Drugs and Listing of Drugs in
Commercial Distribution—(OMB
Control Number 0910–0045—
Amendment)
Description of Respondents:
Respondents to this collection of
information are foreign and domestic
owners and operators of establishments
that engage in the manufacture,
preparation, propagation, compounding,
or processing (which includes, among
other things, repackaging and
relabeling) of a drug or drugs1 and that
are not exempt under section 510(g) of
the Federal Food, Drug, and Cosmetic
Act (the act) or subpart B of part 207 (21
CFR part 207) (registrants).
A. Reporting Burden
The draft guidance describes how to
electronically create and submit
Structured Product Labeling (SPL) files
using defined code sets and codes for
establishment registration and drug
listing information (including labeling).
Most information is already required to
be submitted under section 510 of the
act, section 351 of the Public Health
Service Act, and part 207.
Drug establishment registration and
drug listing information and updates to
such information, required under part
207, and certain additional
recommended information are currently
submitted in paper form using Form
FDA 2656 (Registration of Drug
1 Means both human, including biological
products, and animal drugs.
E:\FR\FM\08JAN1.SGM
08JAN1
Federal Register / Vol. 74, No. 5 / Thursday, January 8, 2009 / Notices
erowe on PROD1PC63 with NOTICES
Establishment/Labeler Code
Assignment), Form FDA 2657 (Drug
Product Listing), and Form FDA 2658
(Registered Establishments Report of
Private Label Distributors) (collectively
referred to as FDA Forms; 72 FR 67733,
November 30, 2007).
In addition to the information
collected by the FDA Forms (72 FR
67733, November 30, 2007), the draft
guidance addresses electronic
submission of other required
information as follows:
• For registered foreign drug
establishments, the name, address, and
telephone number of its U.S. agent
(§ 207.40(c));
• The name of each importer that is
known to the establishment (the U.S.
company or individual in the United
States that is an owner, consignee, or
recipient of the foreign establishment’s
drug that is imported into the United
States. An importer does not include the
consumer or patient who ultimately
purchases, receives, or is administered
the drug, unless the foreign
establishment ships the drug directly to
the consumer or the patient) (section
510(i)(1)(A) of the act); and
• The name of each person who
imports or offers for import (the name
of each agent, broker, or other entity,
other than a carrier, that the foreign
drug establishment uses to facilitate the
import of their drug into the United
States) (section 510(i)(1)(A) of the act).
FDA also is recommending the
voluntary submission of the following
additional information, when
applicable:
• To facilitate correspondence
between foreign establishments and
FDA, the e-mail address for the U.S.
agent, and the telephone number(s) and
e-mail address for the importer and
person who imports or offers for import
their drug;
• A site-specific D-U-N-S® Number2
for each entity (e.g., the registrant,
establishments, U.S. agent, importer);
• The National Drug Code product
code for the source drug that is repacked
or relabeled;
• Distinctive characteristics of certain
listed drugs, i.e., the flavor, the color,
and image of the actual solid dosage
form; and
• Registrants may indicate that they
view as confidential the registrant’s
business relationship with an
establishment, or an inactive ingredient.
2 D&B® D-U-N-S® Number is a unique nine-digit
sequence recognized as the universal standard for
identifying and keeping track of over 100 million
businesses worldwide. Submitting the site-specific
D-U-N-S® Number for an entity would provide by
reference to the number certain business
information for that entity, e.g., address, parentage.
VerDate Nov<24>2008
13:57 Jan 07, 2009
Jkt 217001
In addition to the collection of
information, there is additional burden
for the following activities:
• Preparing a standard operating
procedure (SOP) for the electronic
submission of drug establishment
registration and drug listing
information;
• Creating the SPL file, including
accessing and reviewing the technical
specifications and instructional
documents provided by FDA (accessible
at https://www.fda.gov/oc/datacouncil/
spl.html);
• Reviewing and selecting
appropriate terms and codes used to
create the SPL file (accessible at https://
www.fda.gov/oc/datacouncil/spl.html);
• Obtaining the digital certificate
used with FDA’s electronic submission
gateway (ESG) and uploading the SPL
file for submission (accessible at https://
www.fda.gov/esg/default.htm); and
• Requests for waivers from the
electronic submission process as
described in the draft guidance.
B. Burden Estimates
Reporting Burden—The estimates for
the number of respondents, annual
frequency per response, and total
annual responses indicated in table 1 of
this document are based on our current
estimates of the number of registrants
and the number of submissions using
the FDA Forms (OMB Control No. 0910–
0045). FDA estimates that it would take
an additional 2 hours per response (in
addition to the estimated 2.5 hours per
response for registering, labeler code
requests, listing, and providing updates
to the information approved under OMB
Control No. 0910–0045) for the
collection of information not currently
submitted using the FDA Forms, and to
create and upload the SPL file. FDA
anticipates that the hours per response
will decrease over time due to the
flexibility of submitting information for
registering multiple establishments or
listing multiple drugs in one SPL file
instead of submitting individual FDA
Forms, and increasing familiarity with
the use of the standards and code sets
and codes for creating the SPL file.
In certain cases, if it is unreasonable
to expect a person to submit registration
and listing information electronically,
FDA may grant a waiver from the
electronic format requirement. Because
registrants will only need a computer
and access to the Internet, FDA
envisions few instances in which
electronic submission of registration
and listing information will not be
reasonable for the person requesting the
waiver and, thus, is estimating that FDA
would grant one waiver annually. We
estimate that a one-time burden for
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
817
requesting a waiver would be an hour of
time for a mid-level manager to draft,
approve, and mail a letter.
Recordkeeping Burden—In table 2 of
this document, FDA estimates that 3,295
(39 + 3,256) respondents would expend
a one-time burden of approximately 40
hours in preparing, reviewing, and
approving an SOP for creating and
uploading the SPL file; and an estimated
1 hour annually to maintain the SOP as
needed.
In the Federal Register of July 11,
2008 (73 FR 39964), FDA published a
notice of availability of the draft
guidance document providing a 60-day
public comment period on the
information collection provisions.
Nineteen comments were received of
which four remarked on the information
collection. Thereafter, in the Federal
Register of October 23, 2008 (73 FR
63158), FDA published a 30-day notice
responding to the comments submitted
on the proposed collection of
information and announced that the
proposed collection of information had
been submitted to OMB. In response to
a request by OMB, FDA is republishing
the 30-day notice responding to
comments and announcing the
submission of the proposed collection of
information to OMB.
(Comment 1) On the topic whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have a practical
utility, one comment agreed that the
proposed collection of information is
necessary for us to perform its functions
and is consistent with the provisions of
the Food and Drug Administration
Amendments Act of 2007 (Public Law
110–85). The comment continued to say
that the information is also necessary to
support the transition from paper format
to electronic format, and that the
additional information requested by us
is logical and reasonable and is not an
undue burden.
(Response) We appreciate the support
and concurrence of the comment.
(Comment 2) On the topic whether
the accuracy of FDA’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used,
one comment stated that we
underestimated the effort to prepare,
review, approve, implement and
maintain internal SOPs for electronic
submission of drug establishment
registration and drug listing information
because of the following reason.
Particularly for most large companies,
drug establishment registration and drug
listing information (currently submitted
in paper format under 21 CFR 207.22)
E:\FR\FM\08JAN1.SGM
08JAN1
818
Federal Register / Vol. 74, No. 5 / Thursday, January 8, 2009 / Notices
and content of labeling (currently
submitted in electronic format under 21
CFR 314.50(l)(1)(i)) are handled by
completely different functional experts
and/or departments in the companies.
To coordinate these processes,
additional time is needed to define new
procedures and interactions that cross
functional departments and possibly
international groups. Therefore, large
companies will expend more than 40
hours to prepare, review, approve,
implement and maintain SOPs.
Another comment asserts that the
hours per response in table 1 are
underestimated if the estimate accounts
for the time required to become familiar
with the Structured Product Labeling
(SPL) standard.
(Response) In estimating hours per
record in table 2 of this document, we
considered the various sizes of entities
affected and proposed an average
number of hours per activity. For
example, the estimated 40 hours per
record are based on smaller entities
requiring approximately 20 hours per
record and larger entities requiring
approximately 60 hours per record.
Therefore, because the comment did not
provide a revised estimate, we are
maintaining an estimate of 40 hours per
record, which is consistent with
preparing SOPs for paper format
submissions and also includes
coordination efforts.
Regarding the comment on
underestimating the hours per response
in table 1, the software designed to
create the SPL files, the step-by-step
instructions in the technical guides, and
our technical assistance email address
are provided by us for the purpose of
minimizing the need to learn the SPL
standard before submitting information
electronically.
In this document, we are correcting an
error in table 1 under the hours per
response column. Although the written
description of the burden added 2 hours
to the existing 2.5 hours approved by
OMB under Control Number 0910–0045
(for a total of 4.5 hours), 4.5 hours was
not correctly reproduced in table 1. The
total hours column is also adjusted to
reflect this correction.
(Comment 3) On the topic of ways to
minimize the burden of the collection
on respondents, including through the
use of automated collection techniques,
when appropriate, and other forms of
information technology, one comment
encouraged us to continue the
availability of Xforms at no cost for
industry to use as a software tool for the
creation of SPL. The comment also
requested that we continue this practice
as technology evolves and provide
support for this tool.
(Response) We appreciate the
encouragement of the comment and will
consider the request to continue the
practice and provide support as
technology evolves.
(Comment 4) Two comments did not
agree with our statement that there are
no capital or operating and maintenance
costs associated with the collection of
information. The comments explained
that some companies may choose
alternative tools to the Xform software
or work with external conversion
providers, which may involve the
purchase and maintenance of software
plus the use of internal information
technology personnel for installation,
configuration and maintenance. These
comments further stated that these costs
are significant and need to be
considered in the overall cost for
industry to comply with the electronic
submission requirement.
(Response) As the comments stated,
companies may choose to use
alternative tools or work with external
conversion providers. We do not
disagree. However, we have made every
effort to eliminate costs to industry to
comply with the statutory requirement
to electronically submit drug
establishment registration and drug
listing information.
We also received comments that were
specifically related to the technical
documents referenced in the draft
guidance. Although these comments are
not directly related to the draft guidance
document that contains the information
collection, we will consider the
comments when reviewing the technical
documents for revision.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
Activity
Annual Frequency per
Response
No. of Respondents
Total Annual
Responses
Hours per
Response
Total Hours
New registrations, including new labeler code requests
39
14.72
574
4.5
2,583
Annual updates of registration information
3,256
2.99
9,735
4.5
43,807.5
New drug listings
1,567
6.57
10,295
4.5
46,327.5
146
10.06
1,469
4.5
6,610.5
1,677
11.21
18,799
4.5
84,595.5
1
1
1
1
New listings for private label distributors
June and December updates of all
drug listing information
Waiver requests
Total
1There
1
183,924
are no capital costs or operating and maintenance costs associated with this collection of information.
erowe on PROD1PC63 with NOTICES
TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
Activity
No. of Recordkeepers
Annual Frequency per
Recordkeeping
3,295
1
One-time preparation of SOP
VerDate Nov<24>2008
13:57 Jan 07, 2009
Jkt 217001
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
Total Annual
Records
Hours per
Record
3,295
E:\FR\FM\08JAN1.SGM
08JAN1
Total Hours
40
131,800
819
Federal Register / Vol. 74, No. 5 / Thursday, January 8, 2009 / Notices
TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1—Continued
Activity
No. of Recordkeepers
Annual Frequency per
Recordkeeping
3,295
1
SOP maintenance
Total Annual
Records
Hours per
Record
3,295
Total Hours
1
Total
1There
135,095
are no capital costs or operating and maintenance costs associated with this collection of information.
C. Costs Associated With Electronic
Submission
There are no capital costs or operating
and maintenance costs associated with
the transition from paper to electronic
submissions. To create an SPL file and
submit it to FDA, a registrant would
need the following tools: A computer,
appropriate software, access to the
Internet, knowledge of terminology and
standards, and access to FDA’s ESG.
Registrants (and most individuals)
have computers and Internet access
available for their use. If a business does
not have an available computer or
access to the Internet, free use of
computers and Internet are usually
available at public facilities, e.g., a
community library; or they may request
a waiver from submitting the
information electronically. Software is
necessary to create a ‘‘document.’’ The
SPL file or ‘‘document’’ may be created
internally by a business with experience
with SPL, or a business may use a userfriendly software (XForms)3 available at
no cost for industry use. In addition to
the software, FDA also provides
technical assistance, and other
resources, code sets and codes, and data
standards regarding SPL files.4
Once the SPL file is created, the
registrant would upload the file through
the ESG. A digital certificate is needed
to use the ESG. The digital certificate
binds together the owner’s name and a
pair of electronic keys (a public key and
a private key) that can be used to
encrypt and sign documents. However,
a small fee of up to $20.00 is charged
for the digital certificate and the
registrant may need to renew the
certificate not less than annually. FDA
is not calculating this small fee as cost
of doing business because it is less than
or equal to the biannual courier costs
the registrant incurs for paper
submissions.
erowe on PROD1PC63 with NOTICES
3,295
3 See https://www.fda.gov/oc/datacouncil/
xforms.html.
4 See https://www.fda.gov/oc/datacouncil/
spl.html.
VerDate Nov<24>2008
13:57 Jan 07, 2009
Jkt 217001
Dated: December 22, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–108 Filed 1–7–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Indian Health Service
[Funding Announcement Number: HHS–
2009–IHS–NIHB–0001]
Office of Tribal Program;
Announcement Type: Competing
Continuation
Catalog of Federal Domestic Assistance
Numbers (s): 93.933
Key Dates: Application Deadline Date:
January 9, 2009
Review Date: January 16, 2009
Results Notification: January 21, 2009
Earliest Anticipated Start Date:
February 1, 2009
I. Funding Opportunity Description
Authority: The Indian Health Service (IHS)
announces that a Single Source cooperative
agreement is open for receipt of an
application from the National Indian Health
Board. This program is authorized under
Public Health Service Act, 42 U.S.C. 301.
This program is described at 93.933 in the
Catalog of Federal Domestic Assistance
(CFDA). Purpose: The Office of Tribal
Programs (OTP) has designated funds for the
Single Source National Indian Health Board
(NIHB) to further health program objectives
in the American Indian/Alaska Native (AI/
AN) community with outreach and education
efforts in the interest of improving Indian
health care. The NIHB is the only national
Indian organization with expertise on the
variety of issues related to the provision of
health care to Indian people.
The NIHB represents all 562–
Federally recognized tribes: including
Tribal governments operating their own
health care delivery systems through
self-determination agreements with the
IHS and tribes that continue to receive
health care directly from the IHS. The
NIHB is governed by twelve elected
Tribal Government Officials who
represent each of the twelve IHS Areas
and the HHS regions where Federally
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
recognized Tribes exist. The NIHB is the
only national organization with an
expertise in health policy and health
programs, and the only national
organization with the designated
authority to represent all AI/AN tribes
and villages. The NIHB has a national
constituency and clearly supports
critical services and activities within the
IHS mission of quality health care for
AI/AN people. The NIHB provides
policy analysis and development,
program assessment and development,
regional and national meeting
coordination, consultation and health
care advocacy to IHS and HHS based on
tribal input through a broad based
consumer network. Furthermore, the
NIHB also provides planning and
technical assistance to Tribes, Area
Health Boards, and other Tribal
organizations through the cooperative
agreement with the IHS.
II. Award Information
Type of Award: Cooperative
Agreement. A cooperative agreement
will be awarded as the OTP staff will
have substantial programmatic
involvement with the recipient in
carrying out the project as noted in the
following delineated roles of
involvement to further IHS’ health
program objectives in the AI/AN
community with outreach and
education efforts in the interest of
improving Indian health care.
Cooperative Agreement—Involvement
of Parties
This project is a cooperative
agreement between the IHS and the
NIHB.
Selected entity is responsible for the
following:
1. To provide technical advice in the
area of health care policy analysis and
program development on which IHS
needs to take action;
2. To provide consultation that is
representative of all Tribal governments
in the area of health care policy analysis
and program development;
3. To assure that health care advocacy
is based on Tribal input through a broad
based consumer network involving the
Area Indian Health Boards or Health
E:\FR\FM\08JAN1.SGM
08JAN1
]]>Agencies
[Federal Register Volume 74, Number 5 (Thursday, January 8, 2009)]
[Notices]
[Pages 816-819]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-108]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2005-N-0464] (formerly Docket No. 2005N-0403)
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Draft Guidance for
Industry on Providing Regulatory Submissions in Electronic Format--Drug
Establishment Registration and Drug Listing
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by
February 9, 2009.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974, or e-mailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0045.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Information
Management (HFA-710), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-796-3794.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Draft Guidance for Industry on Providing Regulatory Submissions in
Electronic Format--Drug Establishment Registration and Drug Listing;
Availability; Registration of Producers of Drugs and Listing of Drugs
in Commercial Distribution--(OMB Control Number 0910-0045--Amendment)
Description of Respondents: Respondents to this collection of
information are foreign and domestic owners and operators of
establishments that engage in the manufacture, preparation,
propagation, compounding, or processing (which includes, among other
things, repackaging and relabeling) of a drug or drugs\1\ and that are
not exempt under section 510(g) of the Federal Food, Drug, and Cosmetic
Act (the act) or subpart B of part 207 (21 CFR part 207) (registrants).
---------------------------------------------------------------------------
\1\ Means both human, including biological products, and animal
drugs.
---------------------------------------------------------------------------
A. Reporting Burden
The draft guidance describes how to electronically create and
submit Structured Product Labeling (SPL) files using defined code sets
and codes for establishment registration and drug listing information
(including labeling). Most information is already required to be
submitted under section 510 of the act, section 351 of the Public
Health Service Act, and part 207.
Drug establishment registration and drug listing information and
updates to such information, required under part 207, and certain
additional recommended information are currently submitted in paper
form using Form FDA 2656 (Registration of Drug
[[Page 817]]
Establishment/Labeler Code Assignment), Form FDA 2657 (Drug Product
Listing), and Form FDA 2658 (Registered Establishments Report of
Private Label Distributors) (collectively referred to as FDA Forms; 72
FR 67733, November 30, 2007).
In addition to the information collected by the FDA Forms (72 FR
67733, November 30, 2007), the draft guidance addresses electronic
submission of other required information as follows:
For registered foreign drug establishments, the name,
address, and telephone number of its U.S. agent (Sec. 207.40(c));
The name of each importer that is known to the
establishment (the U.S. company or individual in the United States that
is an owner, consignee, or recipient of the foreign establishment's
drug that is imported into the United States. An importer does not
include the consumer or patient who ultimately purchases, receives, or
is administered the drug, unless the foreign establishment ships the
drug directly to the consumer or the patient) (section 510(i)(1)(A) of
the act); and
The name of each person who imports or offers for import
(the name of each agent, broker, or other entity, other than a carrier,
that the foreign drug establishment uses to facilitate the import of
their drug into the United States) (section 510(i)(1)(A) of the act).
FDA also is recommending the voluntary submission of the following
additional information, when applicable:
To facilitate correspondence between foreign
establishments and FDA, the e-mail address for the U.S. agent, and the
telephone number(s) and e-mail address for the importer and person who
imports or offers for import their drug;
A site-specific D-U-N-S[reg] Number\2\ for each entity
(e.g., the registrant, establishments, U.S. agent, importer);
---------------------------------------------------------------------------
\2\ D&B[reg] D-U-N-S[reg] Number is a unique nine-digit sequence
recognized as the universal standard for identifying and keeping
track of over 100 million businesses worldwide. Submitting the site-
specific D-U-N-S[reg] Number for an entity would provide by
reference to the number certain business information for that
entity, e.g., address, parentage.
---------------------------------------------------------------------------
The National Drug Code product code for the source drug
that is repacked or relabeled;
Distinctive characteristics of certain listed drugs, i.e.,
the flavor, the color, and image of the actual solid dosage form; and
Registrants may indicate that they view as confidential
the registrant's business relationship with an establishment, or an
inactive ingredient.
In addition to the collection of information, there is additional
burden for the following activities:
Preparing a standard operating procedure (SOP) for the
electronic submission of drug establishment registration and drug
listing information;
Creating the SPL file, including accessing and reviewing
the technical specifications and instructional documents provided by
FDA (accessible at https://www.fda.gov/oc/datacouncil/spl.html);
Reviewing and selecting appropriate terms and codes used
to create the SPL file (accessible at https://www.fda.gov/oc/
datacouncil/spl.html);
Obtaining the digital certificate used with FDA's
electronic submission gateway (ESG) and uploading the SPL file for
submission (accessible at https://www.fda.gov/esg/default.htm); and
Requests for waivers from the electronic submission
process as described in the draft guidance.
B. Burden Estimates
Reporting Burden--The estimates for the number of respondents,
annual frequency per response, and total annual responses indicated in
table 1 of this document are based on our current estimates of the
number of registrants and the number of submissions using the FDA Forms
(OMB Control No. 0910-0045). FDA estimates that it would take an
additional 2 hours per response (in addition to the estimated 2.5 hours
per response for registering, labeler code requests, listing, and
providing updates to the information approved under OMB Control No.
0910-0045) for the collection of information not currently submitted
using the FDA Forms, and to create and upload the SPL file. FDA
anticipates that the hours per response will decrease over time due to
the flexibility of submitting information for registering multiple
establishments or listing multiple drugs in one SPL file instead of
submitting individual FDA Forms, and increasing familiarity with the
use of the standards and code sets and codes for creating the SPL file.
In certain cases, if it is unreasonable to expect a person to
submit registration and listing information electronically, FDA may
grant a waiver from the electronic format requirement. Because
registrants will only need a computer and access to the Internet, FDA
envisions few instances in which electronic submission of registration
and listing information will not be reasonable for the person
requesting the waiver and, thus, is estimating that FDA would grant one
waiver annually. We estimate that a one-time burden for requesting a
waiver would be an hour of time for a mid-level manager to draft,
approve, and mail a letter.
Recordkeeping Burden--In table 2 of this document, FDA estimates
that 3,295 (39 + 3,256) respondents would expend a one-time burden of
approximately 40 hours in preparing, reviewing, and approving an SOP
for creating and uploading the SPL file; and an estimated 1 hour
annually to maintain the SOP as needed.
In the Federal Register of July 11, 2008 (73 FR 39964), FDA
published a notice of availability of the draft guidance document
providing a 60-day public comment period on the information collection
provisions. Nineteen comments were received of which four remarked on
the information collection. Thereafter, in the Federal Register of
October 23, 2008 (73 FR 63158), FDA published a 30-day notice
responding to the comments submitted on the proposed collection of
information and announced that the proposed collection of information
had been submitted to OMB. In response to a request by OMB, FDA is
republishing the 30-day notice responding to comments and announcing
the submission of the proposed collection of information to OMB.
(Comment 1) On the topic whether the proposed collection of
information is necessary for the proper performance of FDA's functions,
including whether the information will have a practical utility, one
comment agreed that the proposed collection of information is necessary
for us to perform its functions and is consistent with the provisions
of the Food and Drug Administration Amendments Act of 2007 (Public Law
110-85). The comment continued to say that the information is also
necessary to support the transition from paper format to electronic
format, and that the additional information requested by us is logical
and reasonable and is not an undue burden.
(Response) We appreciate the support and concurrence of the
comment.
(Comment 2) On the topic whether the accuracy of FDA's estimate of
the burden of the proposed collection of information, including the
validity of the methodology and assumptions used, one comment stated
that we underestimated the effort to prepare, review, approve,
implement and maintain internal SOPs for electronic submission of drug
establishment registration and drug listing information because of the
following reason. Particularly for most large companies, drug
establishment registration and drug listing information (currently
submitted in paper format under 21 CFR 207.22)
[[Page 818]]
and content of labeling (currently submitted in electronic format under
21 CFR 314.50(l)(1)(i)) are handled by completely different functional
experts and/or departments in the companies. To coordinate these
processes, additional time is needed to define new procedures and
interactions that cross functional departments and possibly
international groups. Therefore, large companies will expend more than
40 hours to prepare, review, approve, implement and maintain SOPs.
Another comment asserts that the hours per response in table 1 are
underestimated if the estimate accounts for the time required to become
familiar with the Structured Product Labeling (SPL) standard.
(Response) In estimating hours per record in table 2 of this
document, we considered the various sizes of entities affected and
proposed an average number of hours per activity. For example, the
estimated 40 hours per record are based on smaller entities requiring
approximately 20 hours per record and larger entities requiring
approximately 60 hours per record. Therefore, because the comment did
not provide a revised estimate, we are maintaining an estimate of 40
hours per record, which is consistent with preparing SOPs for paper
format submissions and also includes coordination efforts.
Regarding the comment on underestimating the hours per response in
table 1, the software designed to create the SPL files, the step-by-
step instructions in the technical guides, and our technical assistance
email address are provided by us for the purpose of minimizing the need
to learn the SPL standard before submitting information electronically.
In this document, we are correcting an error in table 1 under the
hours per response column. Although the written description of the
burden added 2 hours to the existing 2.5 hours approved by OMB under
Control Number 0910-0045 (for a total of 4.5 hours), 4.5 hours was not
correctly reproduced in table 1. The total hours column is also
adjusted to reflect this correction.
(Comment 3) On the topic of ways to minimize the burden of the
collection on respondents, including through the use of automated
collection techniques, when appropriate, and other forms of information
technology, one comment encouraged us to continue the availability of
Xforms at no cost for industry to use as a software tool for the
creation of SPL. The comment also requested that we continue this
practice as technology evolves and provide support for this tool.
(Response) We appreciate the encouragement of the comment and will
consider the request to continue the practice and provide support as
technology evolves.
(Comment 4) Two comments did not agree with our statement that
there are no capital or operating and maintenance costs associated with
the collection of information. The comments explained that some
companies may choose alternative tools to the Xform software or work
with external conversion providers, which may involve the purchase and
maintenance of software plus the use of internal information technology
personnel for installation, configuration and maintenance. These
comments further stated that these costs are significant and need to be
considered in the overall cost for industry to comply with the
electronic submission requirement.
(Response) As the comments stated, companies may choose to use
alternative tools or work with external conversion providers. We do not
disagree. However, we have made every effort to eliminate costs to
industry to comply with the statutory requirement to electronically
submit drug establishment registration and drug listing information.
We also received comments that were specifically related to the
technical documents referenced in the draft guidance. Although these
comments are not directly related to the draft guidance document that
contains the information collection, we will consider the comments when
reviewing the technical documents for revision.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
Annual Frequency per Total Annual Hours per
Activity No. of Respondents Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
New registrations, 39 14.72 574 4.5 2,583
including new
labeler code
requests
----------------------------------------------------------------------------------------------------------------
Annual updates of 3,256 2.99 9,735 4.5 43,807.5
registration
information
----------------------------------------------------------------------------------------------------------------
New drug listings 1,567 6.57 10,295 4.5 46,327.5
----------------------------------------------------------------------------------------------------------------
New listings for 146 10.06 1,469 4.5 6,610.5
private label
distributors
----------------------------------------------------------------------------------------------------------------
June and December 1,677 11.21 18,799 4.5 84,595.5
updates of all
drug listing
information
----------------------------------------------------------------------------------------------------------------
Waiver requests 1 1 1 1 1
----------------------------------------------------------------------------------------------------------------
Total .................... .................... .................. ............... 183,924
----------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.
Table 2.--Estimated Annual Recordkeeping Burden\1\
----------------------------------------------------------------------------------------------------------------
Annual Frequency per Total Annual Hours per
Activity No. of Recordkeepers Recordkeeping Records Record Total Hours
----------------------------------------------------------------------------------------------------------------
One-time 3,295 1 3,295 40 131,800
preparation of
SOP
----------------------------------------------------------------------------------------------------------------
[[Page 819]]
SOP maintenance 3,295 1 3,295 1 3,295
----------------------------------------------------------------------------------------------------------------
Total .................... .................... .................. ............... 135,095
----------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.
C. Costs Associated With Electronic Submission
There are no capital costs or operating and maintenance costs
associated with the transition from paper to electronic submissions. To
create an SPL file and submit it to FDA, a registrant would need the
following tools: A computer, appropriate software, access to the
Internet, knowledge of terminology and standards, and access to FDA's
ESG.
Registrants (and most individuals) have computers and Internet
access available for their use. If a business does not have an
available computer or access to the Internet, free use of computers and
Internet are usually available at public facilities, e.g., a community
library; or they may request a waiver from submitting the information
electronically. Software is necessary to create a ``document.'' The SPL
file or ``document'' may be created internally by a business with
experience with SPL, or a business may use a user-friendly software
(XForms)\3\ available at no cost for industry use. In addition to the
software, FDA also provides technical assistance, and other resources,
code sets and codes, and data standards regarding SPL files.\4\
---------------------------------------------------------------------------
\3\ See https://www.fda.gov/oc/datacouncil/xforms.html.
\4\ See https://www.fda.gov/oc/datacouncil/spl.html.
---------------------------------------------------------------------------
Once the SPL file is created, the registrant would upload the file
through the ESG. A digital certificate is needed to use the ESG. The
digital certificate binds together the owner's name and a pair of
electronic keys (a public key and a private key) that can be used to
encrypt and sign documents. However, a small fee of up to $20.00 is
charged for the digital certificate and the registrant may need to
renew the certificate not less than annually. FDA is not calculating
this small fee as cost of doing business because it is less than or
equal to the biannual courier costs the registrant incurs for paper
submissions.
Dated: December 22, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-108 Filed 1-7-09; 8:45 am]
BILLING CODE 4160-01-S
